Smith & Nephew SNATS, Inc. (NYSE:SNN) Stock Has Average Target Price of $31.91

Key Points

• Analyst sentiment is cautious: Eleven brokerages give Smith & Nephew an average rating of “Reduce” (two sells, eight holds, and one buy), with an average 12-month price target of $31.91.
• Recent rating changes include downgrades by Wall Street Zen, Barclays, and Morgan Stanley; Berenberg set a $33.88 price target.
• SNN opened at $30.95, near its 200-day moving average of $31.03; its 52-week range is $26.12–$37.09.

Shares of Smith & Nephew SNATS, Inc. (NYSE:SNN - Get Free Report) have been assigned an average rating of "Reduce" from the eleven brokerages that are currently covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and one has issued a buy rating on the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $31.91.

Several analysts have recently commented on SNN shares. Wall Street Zen downgraded shares of Smith & Nephew SNATS from a "buy" rating to a "hold" rating in a report on Saturday. Berenberg Bank set a $33.88 price target on shares of Smith & Nephew SNATS in a report on Friday, September 11th. Barclays downgraded shares of Smith & Nephew SNATS from an "equal weight" rating to an "underweight" rating in a research report on Wednesday, August 5th. Morgan Stanley lowered shares of Smith & Nephew SNATS from an "overweight" rating to an "equal weight" rating in a research note on Wednesday, September 2nd. Finally, Weiss Ratings lowered shares of Smith & Nephew SNATS from a "hold (c+)" rating to a "hold (c)" rating in a research note on Thursday, September 24th.

Smith & Nephew SNATS Price Performance

SNN opened at $30.95 on Wednesday. The company has a quick ratio of 1.11, a current ratio of 2.14 and a debt-to-equity ratio of 0.62. The firm's fifty day moving average price is $28.59 and its two-hundred day moving average price is $31.03. Smith & Nephew SNATS has a 1 year low of $26.12 and a 1 year high of $37.09.

Hedge Funds Weigh In On Smith & Nephew SNATS

Several institutional investors have recently modified their holdings of the business. BlackRock Inc. purchased a new stake in shares of Smith & Nephew SNATS during the second quarter valued at approximately $505,323,000. Bank of America Corp DE purchased a new position in Smith & Nephew SNATS in the second quarter worth $97,223,000. Bank of New York Mellon Corp bought a new position in Smith & Nephew SNATS in the 2nd quarter valued at $89,325,000. Caisse de depot et placement du Quebec purchased a new stake in shares of Smith & Nephew SNATS during the 2nd quarter valued at $64,186,000. Finally, Legal & General Group Plc purchased a new stake in shares of Smith & Nephew SNATS during the 2nd quarter valued at $35,338,000. 25.64% of the stock is owned by institutional investors.

Smith & Nephew SNATS Company Profile

Smith & Nephew plc is a global medical technology company that develops and sells products used in surgery, orthopaedics and wound care. Its offerings include implants for hip and knee replacement, instruments and devices for sports medicine and ear, nose and throat procedures, and products designed to manage wounds and support tissue repair. Founded in 1856 in Hull, England, the company began as a pharmacy business before expanding into medical products. It now serves healthcare providers and patients in markets around the world.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.